Imagine a hidden world of microscopic detectives working around the clock—that's the laboratory diagnostics industry, a massive $85 billion global force projected to grow to over $123 billion by 2030 as it transforms how we detect and manage disease.
Key Takeaways
- The global laboratory diagnostics market was valued at USD 85.04 billion in 2023 and is projected to reach USD 123.32 billion by 2030, growing at a CAGR of 5.4%.
- In 2022, the in vitro diagnostics (IVD) market size stood at USD 81.28 billion, expected to expand to USD 112.65 billion by 2030 at a CAGR of 4.2%.
- North America's laboratory diagnostics market generated revenue of USD 32.5 billion in 2023, with a forecasted CAGR of 5.1% through 2028.
- Infectious disease testing accounted for 26.3% of the global IVD market share in 2023.
- Clinical chemistry segment held 25.8% revenue share in the laboratory diagnostics market in 2023.
- Immunoassays represented 32.4% of the IVD market by product type in 2023.
- Roche Diagnostics held 14.2% market share in the global IVD market in 2023.
- Abbott Laboratories captured 12.8% share of the laboratory diagnostics market in 2023.
- Siemens Healthineers accounted for 11.5% revenue share in IVD globally in 2023.
- North America dominated the laboratory diagnostics market with 38.2% revenue share in 2023.
- U.S. IVD market generated USD 30.1 billion in 2023, holding 35.4% of North American share.
- Europe laboratory diagnostics market was valued at USD 24.8 billion in 2023, with Germany leading at 22.1% regional share.
- Point-of-care diagnostics adoption grew by 15.2% in rural Asia-Pacific regions in 2023.
- AI integration in lab diagnostics improved diagnostic accuracy by 22.4% in clinical trials during 2023.
- NGS-based tests for cancer diagnostics increased by 28.7% year-over-year in 2023.
The global laboratory diagnostics industry is experiencing significant growth across multiple segments and regions.
Key Companies
- Roche Diagnostics held 14.2% market share in the global IVD market in 2023.
- Abbott Laboratories captured 12.8% share of the laboratory diagnostics market in 2023.
- Siemens Healthineers accounted for 11.5% revenue share in IVD globally in 2023.
- Danaher Corporation (Beckman Coulter) held 9.7% market share in clinical diagnostics in 2023.
- Thermo Fisher Scientific occupied 8.4% share in molecular diagnostics in 2023.
- Becton Dickinson & Company (BD) had 7.9% share in hematology diagnostics in 2023.
- Bio-Rad Laboratories captured 6.3% of the clinical chemistry market in 2023.
- Ortho Clinical Diagnostics held 5.8% share in immunoassays in 2023.
- bioMérieux SA accounted for 5.2% in microbiology testing market in 2023.
- Hologic Inc. had 4.9% share in molecular diagnostics for infectious diseases in 2023.
- Sysmex Corporation captured 10.1% of hematology analyzers market in 2023.
- Arkray Inc. held 4.6% in point-of-care diagnostics in 2023.
- Qiagen NV accounted for 7.3% in PCR diagnostics market in 2023.
- Illumina Inc. had 15.4% share in NGS diagnostics in 2023.
- PerkinElmer Inc. captured 4.1% in newborn screening diagnostics in 2023.
- Agilent Technologies held 6.7% in mass spectrometry diagnostics in 2023.
- Luminex Corporation accounted for 3.9% in flow cytometry market in 2023.
- DiaSorin Inc. had 5.5% share in immunodiagnostics in 2023.
- Fujirebio Diagnostics Inc. captured 2.8% in tumor marker testing in 2023.
- Grifols SA held 4.3% in transfusion diagnostics in 2023.
- BioMerieux held 6.2% in coagulation testing market in 2023.
- Randox Laboratories accounted for 3.7% in clinical chemistry reagents in 2023.
Key Companies Interpretation
While Roche Diagnostics may wear the overall IVD crown, the laboratory diagnostics landscape is a fiercely competitive chessboard where giants like Abbott and Siemens jockey for position, while a host of specialized kings, from Illumina in NGS to Sysmex in hematology, firmly rule their own carefully carved domains.
Market Segments
- Infectious disease testing accounted for 26.3% of the global IVD market share in 2023.
- Clinical chemistry segment held 25.8% revenue share in the laboratory diagnostics market in 2023.
- Immunoassays represented 32.4% of the IVD market by product type in 2023.
- Point-of-care testing captured 28.7% market share in diagnostics in 2023.
- Molecular diagnostics held 12.5% share of the total lab diagnostics market in 2023.
- Hematology analyzers accounted for 22.1% of the hematology diagnostics segment in 2023.
- Reagents dominated with 68.4% share in the IVD market in 2023.
- Hospital end-use segment had 45.2% revenue share in lab diagnostics in 2023.
- Diabetes segment occupied 18.9% of the IVD application market in 2023.
- Oncology diagnostics represented 15.6% market share in molecular diagnostics in 2023.
- Microbiology segment held 14.3% of the total diagnostics market in 2023.
- Consumables accounted for 55.7% share in lab automation market in 2023.
- PCR tests comprised 41.2% of molecular diagnostics technologies in 2023.
- Blood testing segment had 62.4% share in point-of-care diagnostics in 2023.
- Tissue diagnostics reagents held 48.9% market share in 2023.
- Coagulation analyzers represented 33.7% of hemostasis diagnostics in 2023.
- Urinalysis strips occupied 29.5% segment share in 2023.
- Companion diagnostics for oncology had 52.3% application share in 2023.
- Flow cytometry reagents accounted for 39.8% of the market in 2023.
- Infectious disease immunoassays held 37.1% share in immunodiagnostics in 2023.
- Digital pathology software had 26.4% segment share in 2023.
- Mass spectrometry clinical analyzers represented 44.2% in 2023.
- ELISA kits for infectious diseases occupied 31.6% in 2023.
- Biosensors for glucose monitoring had 45.9% share in 2023.
- Cardiac biomarker tests accounted for 28.3% of cardiac diagnostics in 2023.
Market Segments Interpretation
In a 2023 diagnostic landscape held together by reagents (68.4%) and ruled by hospitals (45.2%), the perennial battle between the reigning immunoassay king (32.4%) and the point-of-care insurgent (28.7%) unfolds, while the persistent shadow of infectious disease (26.3%) ensures the lab's lights never truly go off.
Market Size & Growth
- The global laboratory diagnostics market was valued at USD 85.04 billion in 2023 and is projected to reach USD 123.32 billion by 2030, growing at a CAGR of 5.4%.
- In 2022, the in vitro diagnostics (IVD) market size stood at USD 81.28 billion, expected to expand to USD 112.65 billion by 2030 at a CAGR of 4.2%.
- North America's laboratory diagnostics market generated revenue of USD 32.5 billion in 2023, with a forecasted CAGR of 5.1% through 2028.
- The clinical chemistry segment of the lab diagnostics market was valued at USD 28.6 billion in 2023, projected to grow at 5.8% CAGR to 2030.
- Global point-of-care diagnostics market reached USD 42.67 billion in 2023, anticipated to hit USD 68.3 billion by 2030 at 6.9% CAGR.
- The molecular diagnostics market size was USD 17.79 billion in 2023, expected to grow to USD 32.09 billion by 2032 at a CAGR of 6.8%.
- Immunodiagnostics market valued at USD 24.5 billion in 2022, projected CAGR of 7.2% to reach USD 43.8 billion by 2030.
- Lab automation market size was USD 4.8 billion in 2023, forecasted to reach USD 7.2 billion by 2030 at 6.0% CAGR.
- Tissue diagnostics market stood at USD 5.3 billion in 2023, expected to grow at 7.5% CAGR to USD 9.1 billion by 2030.
- The hematology diagnostics market was valued at USD 4.2 billion in 2023, projected to reach USD 6.1 billion by 2030 at 5.5% CAGR.
- Microbiology testing market size reached USD 6.8 billion in 2023, anticipated CAGR of 6.2% to USD 10.2 billion by 2030.
- Coagulation testing market valued at USD 3.9 billion in 2022, expected to grow at 6.7% CAGR to USD 6.5 billion by 2030.
- The global urinalysis market was USD 1.4 billion in 2023, projected to reach USD 2.1 billion by 2030 at 5.9% CAGR.
- Clinical diagnostics market size hit USD 72.3 billion in 2023, forecasted CAGR 4.8% to USD 102.5 billion by 2032.
- Companion diagnostics market valued at USD 7.8 billion in 2023, expected to expand at 12.4% CAGR to USD 18.9 billion by 2030.
- The lab diagnostics market in Europe was USD 22.1 billion in 2023, growing at 4.9% CAGR to 2030.
- Asia-Pacific IVD market reached USD 18.7 billion in 2023, projected CAGR 7.1% to USD 31.4 billion by 2030.
- Latin America lab diagnostics market size was USD 4.2 billion in 2023, expected 5.3% CAGR growth.
- Middle East & Africa diagnostics market valued at USD 3.5 billion in 2023, forecasted 6.0% CAGR.
- Digital pathology market size stood at USD 1.1 billion in 2023, projected to USD 2.4 billion by 2030 at 12.0% CAGR.
- Next-generation sequencing for diagnostics market was USD 4.5 billion in 2023, growing at 21.7% CAGR.
- Mass spectrometry market in clinical diagnostics reached USD 5.2 billion in 2023, expected 8.5% CAGR.
- ELISA market size was USD 2.8 billion in 2023, forecasted CAGR 4.7% to USD 4.0 billion by 2030.
- PCR technologies market in diagnostics hit USD 8.9 billion in 2023, growing at 8.2% CAGR.
- Biosensors for diagnostics market valued at USD 25.3 billion in 2023, expected 9.8% CAGR to 2030.
- The global IVD market for infectious diseases was USD 22.4 billion in 2023, projected CAGR 6.5%.
- Oncology IVD market size reached USD 9.6 billion in 2023, forecasted 7.9% CAGR to 2030.
- Diabetes diagnostics market was USD 19.2 billion in 2023, growing at 5.6% CAGR.
- Cardiac diagnostics market valued at USD 15.7 billion in 2023, expected 6.3% CAGR to USD 24.1 billion by 2030.
Market Size & Growth Interpretation
While humanity's health is an increasingly expensive equation, the consistent, multi-billion-dollar growth across every diagnostic segment reveals a sobering truth: our collective well-being is now one of the planet's most voracious and data-hungry industries.
Regional Insights
- North America dominated the laboratory diagnostics market with 38.2% revenue share in 2023.
- U.S. IVD market generated USD 30.1 billion in 2023, holding 35.4% of North American share.
- Europe laboratory diagnostics market was valued at USD 24.8 billion in 2023, with Germany leading at 22.1% regional share.
- Asia-Pacific diagnostics market grew at 8.2% CAGR from 2018-2023, valued at USD 20.3 billion in 2023.
- China IVD market size reached USD 12.4 billion in 2023, fastest growing at 9.5% CAGR.
- Japan lab diagnostics market accounted for USD 7.2 billion in 2023, 6.8% regional APAC share.
- India diagnostics market valued at USD 4.1 billion in 2023, projected 12.3% CAGR to 2030.
- Latin America IVD market was USD 4.5 billion in 2023, Brazil holding 45.7% regional share.
- Brazil laboratory diagnostics market generated USD 2.1 billion in 2023, 5.1% CAGR expected.
- Middle East diagnostics market reached USD 2.8 billion in 2023, Saudi Arabia at 31.4% share.
- South Africa IVD market valued at USD 0.9 billion in 2023, growing at 7.2% CAGR.
- Canada lab diagnostics market was USD 2.4 billion in 2023, 7.4% of North America.
- UK diagnostics market accounted for USD 4.3 billion in 2023, 17.3% of Europe.
- France IVD market size hit USD 3.9 billion in 2023, 6.1% CAGR projected.
- Germany dominated Europe with USD 5.5 billion in lab diagnostics revenue in 2023.
- South Korea diagnostics market valued at USD 2.7 billion in 2023, 8.9% CAGR.
- Australia IVD market reached USD 1.8 billion in 2023, 6.5% regional share.
- Mexico lab diagnostics market was USD 1.2 billion in 2023, fastest in LATAM at 6.8% CAGR.
- UAE diagnostics market accounted for USD 1.1 billion in 2023, 39.3% of MEA.
- Russia IVD market size stood at USD 2.9 billion in 2023, 11.7% Europe share.
Regional Insights Interpretation
While North America is still the undisputed heavyweight champion of the lab, flexing its financial muscles, the real plot twist is playing out in the East, where growth is the new currency and every percentage point is a sprint towards the future.
Trends & Innovations
- Point-of-care diagnostics adoption grew by 15.2% in rural Asia-Pacific regions in 2023.
- AI integration in lab diagnostics improved diagnostic accuracy by 22.4% in clinical trials during 2023.
- NGS-based tests for cancer diagnostics increased by 28.7% year-over-year in 2023.
- Lab-on-a-chip technologies saw 18.9% market penetration growth in POC settings in 2023.
- Digital pathology adoption rose 31.5% in hospitals globally in 2023.
- CRISPR-based diagnostics gained 12.3% traction in infectious disease testing in 2023.
- Wearable biosensors for real-time diagnostics grew 25.6% in consumer adoption in 2023.
- Automation in high-throughput labs reduced turnaround time by 40.2% on average in 2023.
- Liquid biopsy tests for oncology surged 34.1% in usage in 2023.
- Multiplex assays adoption increased 19.8% in immunology research in 2023.
- Telepathology platforms saw 27.4% growth in remote diagnostics in 2023.
- Microfluidics in diagnostics enhanced throughput by 33.7% in 2023 studies.
- Blockchain for lab data security implemented in 14.6% of large labs in 2023.
- Single-cell analysis technologies grew 41.2% in adoption for precision medicine in 2023.
- 5G-enabled remote diagnostics reduced latency by 52.3% in POC devices in 2023.
- Nanotechnology in biosensors improved sensitivity by 29.8% for early detection in 2023.
- Cloud-based LIMS adoption rose 23.1% in mid-sized labs in 2023.
- Organ-on-a-chip models advanced 16.5% in toxicological diagnostics in 2023.
- Quantum dot-based imaging enhanced resolution by 37.9% in pathology in 2023.
- mRNA diagnostics for vaccines testing grew 48.7% post-COVID in 2023.
- IoT integration in lab equipment increased efficiency by 21.4% in 2023.
- Personalized diagnostics via pharmacogenomics rose 26.8% in prescriptions in 2023.
- Hyperspectral imaging in diagnostics improved tissue analysis accuracy by 24.3% in 2023.
- Robotic automation in sample prep reduced errors by 35.6% in labs in 2023.
- Aptamer-based sensors gained 17.2% market interest for rapid testing in 2023.
- 3D bioprinting for diagnostic models advanced 22.9% in R&D in 2023.
Trends & Innovations Interpretation
The year 2023 saw diagnostics sprint toward the patient with gadgets in villages and wearables on wrists, while in the lab, AI minds and robot hands quietly revolutionized precision and speed, proving that the future of medicine is both intimately personal and brilliantly automated.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 3MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 4FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 5PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 6GMINSIGHTSgminsights.comVisit source
- Reference 7ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 8SKYQUESTTskyquestt.comVisit source